November 18, 2026
Health news, explained with evidence
LIVE

Scientists map key enzyme linked to rare metabolic disorder glutaric aciduria type 1

🥗 Nutrition 2 min read 👁 6

Researchers at the Icahn School of Medicine at Mount Sinai have mapped the complete structure of the AASS enzyme, offering new structural insights that could guide future drug development for glutaric aciduria type 1 (GA1).

Scientists map key enzyme linked to rare metabolic disorder glutaric aciduria type 1🥗Nutrition

Photo: Medical Xpress

Key points

  • Icahn School of Medicine researchers mapped the complete structure of the AASS enzyme.
  • The study identifies a flexible hinge region that regulates enzyme activity, offering a potential drug target for GA1.
  • Findings are early-stage laboratory results; further animal and human studies are required.

A team of investigators at the Icahn School of Medicine at Mount Sinai has successfully mapped the full structure of the enzyme AASS, which plays a central role in breaking down the amino acid lysine. Published in Science Advances, the study reveals how specific regulatory regions control the enzyme's activity, potentially paving the way for targeted therapies against glutaric aciduria type 1 (GA1), a rare inherited metabolic condition.

GA1 causes toxic metabolites to accumulate inside the body, which can trigger irreversible brain damage and severe neurological complications. By isolating the complete human enzyme and utilizing advanced techniques such as cryo-electron microscopy alongside computer simulations, the researchers generated high-resolution visualizations of AASS. They discovered a hinge-like region where minor structural adjustments significantly alter the protein's function, offering a promising target for future drug inhibitors.

The study authors emphasize that these findings represent an early laboratory step rather than a proven treatment or cure. Because the work was conducted in vitro, subsequent investigations involving animal and eventually human studies will be necessary to establish safety and clinical efficacy. Readers should consult qualified healthcare professionals regarding personal medical questions or genetic conditions.

  • What to know: Mount Sinai researchers mapped the structure of the AASS enzyme to better understand lysine breakdown and explore drug targets for GA1.
  • Study methods: Scientists used cryo-electron microscopy, biochemical experiments, and computer simulations to analyze the enzyme.
  • Limitations: The findings are strictly early-stage laboratory results and do not constitute a cure or available treatment.

Source Medical Xpress — medicalxpress.com/news/2026-11-enzyme-clues-rare-genetic-disease.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.